Exabis Library
Welcome to the e-CCO Library!
P420 A randomised, observer-blinded phase Ib multiple, ascending dose study of UTTR1147A, an IL-22Fc fusion protein, in healthy volunteers and ulcerative colitis patients
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P420: Anti-TNF for post-operative prevention in Crohn's disease: the detection of anti-drug antibodies at time of surgery is associated with an increased risk of endoscopic recurrence
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P420: Comparative efficacy and safety of oral ferric maltol in Inflammatory Bowel Disease patients with mild-to-moderate vs. more severe iron deficiency anaemia
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P420: Correlation between Infliximab trough levels and endoscopic activity in ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P420: Does vedolizumab change mural vascularisation in ulcerative colitis and is there a correlation with endoscopic findings?
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P420: Effectiveness and safety of biosimilar infliximab (remsima) in a real-life setting in 84 patients with Crohn’s disease and ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P420: Long term efficacy of ustekinumab in Crohn's disease patients after vedolizumab failure
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P420: Safety & feasibility of targeted mesenteric approaches to ileocolic resection and anastomosis in Crohn's Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P421 Prognostic and therapeutic long-term outcome of patients with ulcerative proctitis: analysis from a large referral centre cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P421: Comparative efficacy and impact on patient-reported outcomes of pharmacological therapies for moderate to severe ulcerative colitis: a systematic review and network meta-analysis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P421: Correlation of bowel activity parameters in intestinal ultrasound to drug retention and trough drug levels in Crohn's disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P421: Effects of combination therapy in inflammatory bowel disease: how long should we keep concomitant immunomodulators?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P421: Real-world effectiveness and safety of vedolizumab induction therapy for Crohn's disease in Poland – a prospective, observational POLONEZ II study considering patient-reported outcomes
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P421: SER-287, an investigational microbiome therapeutic, induces remission and endoscopic improvement in a placebo-controlled, double-blind randomised trial in patients with active mild-to-moderate ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P421: Skin side effects of biologic therapy and systemic drugs in patients with inflammatory bowel diseases
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P421: Treatment optimization with vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn’s disease – a real-world two-center cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P422 Tofacitinib induces clinical and endoscopic remission in biologic refractory ulcerative colitis patients: a real-world Belgian cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P422: COVID 19 infection in IBD patients treated with biologic therapy-experience from tertiary center in Serbia
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P422: How achievable are the STRIDE-II treatment targets in real-world practise and do they affect outcome?
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P422: Immunogenicity of a proposed adalimumab biosimilar, FKB327, and the reference product in patients with rheumatoid arthritis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM